190 related articles for article (PubMed ID: 30864294)
1. Occurrence of CYP2B6 516G>T polymorphism in patients with ARV-associated hepatotoxicity.
Singh H; Lata S; Dhole TN; Gangakhedkar RR
Mol Genet Genomic Med; 2019 Apr; 7(4):e00598. PubMed ID: 30864294
[TBL] [Abstract][Full Text] [Related]
2. Occurrence of Interleukin-2 (330 G/T) Promoter Polymorphism in ARV associated hepatotoxicity.
Singh H; Nambiar N; Samani D; Gangakhedkar RR
Curr Mol Med; 2019; 19(3):206-215. PubMed ID: 30973108
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of the associations of CYP2B6-516G>T polymorphisms with efavirenz-induced central nervous system side effects and virological outcome in HIV-infected adults.
Cheng L; Wang Y; Li X; Feng W; Weng B; Yuan Q; Xia P; Sun F
Pharmacogenomics J; 2020 Apr; 20(2):246-259. PubMed ID: 31636355
[TBL] [Abstract][Full Text] [Related]
4. The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: Lessons from Botswana.
Maseng MJ; Tawe L; Thami PK; Moyo S; Kasvosve I; Novitsky V; Essex M; Russo G; Gaseitsiwe S; Paganotti GM
Medicine (Baltimore); 2022 Apr; 101(17):e29066. PubMed ID: 35512066
[TBL] [Abstract][Full Text] [Related]
5. Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand.
Chaivichacharn P; Avihingsanon A; Manosuthi W; Ubolyam S; Tongkobpetch S; Shotelersuk V; Punyawudho B
Clin Ther; 2020 Jul; 42(7):1234-1245. PubMed ID: 32451120
[TBL] [Abstract][Full Text] [Related]
6. Plasma levels of efavirenz and frequency of the CYP2B6 516G>T polymorphism in people living with HIV-1 in Mexico.
Ortíz-Rodríguez MA; Oaxaca-Navarro J; Patiño-Camacho SI; García-Jiménez S; Déciga-Campos M; Martínez-Salazar MF
Pharmazie; 2022 Jun; 77(6):191-195. PubMed ID: 35751161
[TBL] [Abstract][Full Text] [Related]
7. CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6*9 and CYP2B6*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon.
Paganotti GM; Russo G; Sobze MS; Mayaka GB; Muthoga CW; Tawe L; Martinelli A; Romano R; Vullo V
Infect Genet Evol; 2015 Oct; 35():122-6. PubMed ID: 26247717
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 2B6 genetic variants are associated with plasma nevirapine levels and clinical response in HIV-1 infected Kenyan women: a prospective cohort study.
Oluka MN; Okalebo FA; Guantai AN; McClelland RS; Graham SM
AIDS Res Ther; 2015; 12():10. PubMed ID: 25878720
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.
Kwara A; Lartey M; Sagoe KW; Xexemeku F; Kenu E; Oliver-Commey J; Boima V; Sagoe A; Boamah I; Greenblatt DJ; Court MH
J Clin Pharmacol; 2008 Sep; 48(9):1032-40. PubMed ID: 18728241
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population.
Mahungu T; Smith C; Turner F; Egan D; Youle M; Johnson M; Khoo S; Back Dj; Owen A
HIV Med; 2009 May; 10(5):310-7. PubMed ID: 19228205
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of ABCC3-1767G/A polymorphism among patients with antiretroviral-associated hepatotoxicity.
Singh H; Lata S; Choudhari R; Dhole TN
Mol Genet Genomic Med; 2020 Jun; 8(6):e1124. PubMed ID: 32212330
[TBL] [Abstract][Full Text] [Related]
12. CYP1A1m1 and CYP2C9*2 and *3 polymorphism and risk to develop ARV-associated hepatotoxicity and its severity.
Singh H; Lata S; Nema V; Samani D; Ghate M; Gangakhedkar RR
APMIS; 2017 Jun; 125(6):523-535. PubMed ID: 28370504
[TBL] [Abstract][Full Text] [Related]
13. The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine.
Neary M; Lamorde M; Olagunju A; Darin KM; Merry C; Byakika-Kibwika P; Back DJ; Siccardi M; Owen A; Scarsi KK
Clin Pharmacol Ther; 2017 Sep; 102(3):529-536. PubMed ID: 28187506
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients.
Chou M; Bertrand J; Segeral O; Verstuyft C; Borand L; Comets E; Le Tiec C; Becquemont L; Ouk V; Mentre F; Taburet AM
Antimicrob Agents Chemother; 2010 Oct; 54(10):4432-9. PubMed ID: 20696882
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.
Wyen C; Hendra H; Siccardi M; Platten M; Jaeger H; Harrer T; Esser S; Bogner JR; Brockmeyer NH; Bieniek B; Rockstroh J; Hoffmann C; Stoehr A; Michalik C; Dlugay V; Jetter A; Knechten H; Klinker H; Skaletz-Rorowski A; Fätkenheuer G; Egan D; Back DJ; Owen A;
J Antimicrob Chemother; 2011 Sep; 66(9):2092-8. PubMed ID: 21715435
[TBL] [Abstract][Full Text] [Related]
16. CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy.
Manosuthi W; Sukasem C; Lueangniyomkul A; Mankatitham W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
Int J Antimicrob Agents; 2014 Mar; 43(3):292-6. PubMed ID: 24359841
[TBL] [Abstract][Full Text] [Related]
17. Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique.
Ciccacci C; Borgiani P; Ceffa S; Sirianni E; Marazzi MC; Altan AM; Paturzo G; Bramanti P; Novelli G; Palombi L
Pharmacogenomics; 2010 Jan; 11(1):23-31. PubMed ID: 20017669
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of CYP2D6*4 1934G/A polymorphism in Western Indian HIV patients.
Singh H; Lata S; Gangakhedkar RR
APMIS; 2018 Nov; 126(11):842-851. PubMed ID: 30357957
[TBL] [Abstract][Full Text] [Related]
19. Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients.
Mhandire D; Lacerda M; Castel S; Mhandire K; Zhou D; Swart M; Shamu T; Smith P; Musingwini T; Wiesner L; Stray-Pedersen B; Dandara C
OMICS; 2015 Sep; 19(9):553-62. PubMed ID: 26348712
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-10 polymorphisms and susceptibility to ARV associated hepatotoxicity.
Singh H; Samani D; Nain S; Dhole TN
Microb Pathog; 2019 Aug; 133():103544. PubMed ID: 31121270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
